Prognostic significance of programmed cell death-1-positive cells in follicular lymphoma patients may alter in the rituximab era

European Journal of Haematology

Volumn 90, Issue 4, 2013, Pages 286-290

  Takahashi, Hiroyuki ^a   Tomita, Naoto ^a   Sakata, Seiji ^b   Tsuyama, Naoko ^b   Hashimoto, Chizuko ^c   Ohshima, Rika ^d   Matsuura, Shiro ^e   Ogawa, Koji ^f   Yamamoto, Wataru ^g   Kameda, Yoichi ^c   Enaka, Makiko ^d   Inayama, Yoshiaki ^a   Kasahara, Masao ^e   Takekawa, Yoshinori ^f   Onoda, Noboru ^g   Motomura, Shigeki ^c   Ishigatsubo, Yoshiaki ^a   Takeuchi, Kengo ^b  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CANCER INSTITUTE   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^e SHIZUOKA RED CROSS HOSPITAL   (Japan)

^f Yokosuka City Hospital   (Japan)

^g Yamato Municipal Hospital   (Japan)

Author keywords

Follicular lymphoma; Programmed cell death 1; R CHOP; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; PROGRAMMED DEATH 1 LIGAND 1; RITUXIMAB; T LYMPHOCYTE RECEPTOR; VINCRISTINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BIOPSY; CANCER PROGNOSIS; CANCER SURVIVOR; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; FOLLICULAR LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; FOLLOW UP; HUMAN; IMMUNOLOGICAL TOLERANCE; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STANDARD; SURVIVAL TIME; TUMOR MICROENVIRONMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 84875271751     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12075     Document Type: Article

References (17)

1. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-48.
2. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007;8:239-45.
3. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
4. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562-7.
5. Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003;63:6501-5.
6. Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005;11:2947-53.
7. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007;13:2151-7.
8. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66:3381-5.
9. Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, Hamoudi R, Howat WJ, Montserrat E, Campo E. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009;27:1470-6.
10. Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, Christensson B, Sander B, Kimby E. A unifying microenvironment model in Follicular Lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T Cells and macrophages. Clin Cancer Res 2010;16:637-50.
11. Richendollar BG, Pohlman B, Elson P, Hsi ED. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum Pathol 2011;42:552-7.
12. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
13. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, Montserrat E, Campo E, Banham AH. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006;108:2957-64.
14. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, Klasa R, Voss N, Connors JM, Gascoyne RD. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-74.
15. Stroopinsky D, Kats T, Rowe JM, Melamed D, Avivi I. Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother 2012;61:1233-41.
16. Müller C, Murawski N, Wiesen MHJ, Held G, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012;119:3276-84.
17. Jäger U, Fridrik M, Zeitlinger M, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 2012;97:1431-8.